NCT02049281View on ClinicalTrials.gov

A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Solid Tumor
Interventions
DRUG

Vintafolide

Intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.

Sponsors

Lead Sponsor

Endocyte
All Listed Sponsors
lead

Endocyte

INDUSTRY